Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented JenaValve Technology in the transaction. Involved fees earner: Heather Aune – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian;...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented BillionToOne in the transaction. BillionToOne, a next-generation molecular diagnostics company, announced it has raised $130 million in Series...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery represented Veradigm Inc. in the transaction, and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented ScienceIO. Veradigm Inc. (NASDAQ: MDRX) (the “Company”),...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Colossal Biosciences on the deal. Colossal Biosciences, a genetic engineering company, announced its $150 million Series B financing led by United States Innovative Technology...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented BillionToOn on the deal. BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented BillionToOne on the deal. BillionToOne, a next-generation molecular diagnostics company, announced the $125 million Series C financing co-led by Adams Street Partners and Hummingbird...
You must be a Standard 1 Year member to access this content.
JPMorgan Chase Bank, N.A. and Credit Suisse AG acted as financial advisors to Taboola. JPMorgan Chase Bank, N.A. and Credit Suisse AG are providing committed debt...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Xoma Corporation on the deal. Vischer advised Kuros Biosciences AG. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator, announced the acquisition of the royalty interest...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Merck on the deal. Merck, known as MSD outside the United States and Canada, announced a definitive agreement with Alydia Health, a commercial-stage medical...
You must be a Standard 1 Year member to access this content.
Paul Hastings LLP advised Xoma Corporation on the deal. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator announced its multi-license and milestone monetization transaction with Viracta Therapeutics....
You must be a Standard 1 Year member to access this content.
